Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Warsaw, Poland.
Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
Clin Epigenetics. 2023 Feb 27;15(1):29. doi: 10.1186/s13148-023-01446-4.
Glioblastoma (GBM, WHO grade IV) is an aggressive, primary brain tumor. Despite extensive tumor resection followed by radio- and chemotherapy, life expectancy of GBM patients did not improve over decades. Several studies reported transcription deregulation in GBMs, but regulatory mechanisms driving overexpression of GBM-specific genes remain largely unknown. Transcription in open chromatin regions is directed by transcription factors (TFs) that bind to specific motifs, recruit co-activators/repressors and the transcriptional machinery. Identification of GBM-related TFs-gene regulatory networks may reveal new and targetable mechanisms of gliomagenesis.
We predicted TFs-regulated networks in GBMs in silico and intersected them with putative TF binding sites identified in the accessible chromatin in human glioma cells and GBM patient samples. The Cancer Genome Atlas and Glioma Atlas datasets (DNA methylation, H3K27 acetylation, transcriptomic profiles) were explored to elucidate TFs-gene regulatory networks and effects of the epigenetic background. In contrast to the majority of tumors, c-Jun expression was higher in GBMs than in normal brain and c-Jun binding sites were found in multiple genes overexpressed in GBMs, including VIM, FOSL2 or UPP1. Binding of c-Jun to the VIM gene promoter was stronger in GBM-derived cells than in cells derived from benign glioma as evidenced by gel shift and supershift assays. Regulatory regions of the majority of c-Jun targets have distinct DNA methylation patterns in GBMs as compared to benign gliomas, suggesting the contribution of DNA methylation to the c-Jun-dependent gene expression.
GBM-specific TFs-gene networks identified in GBMs differ from regulatory pathways attributed to benign brain tumors and imply a decisive role of c-Jun in controlling genes that drive glioma growth and invasion as well as a modulatory role of DNA methylation.
胶质母细胞瘤(GBM,IV 级)是一种侵袭性原发性脑肿瘤。尽管广泛的肿瘤切除后进行放射和化学治疗,但 GBM 患者的预期寿命在几十年内并没有改善。几项研究报告了 GBM 中的转录失调,但驱动 GBM 特异性基因过表达的调节机制在很大程度上仍然未知。开放染色质区域中的转录由转录因子(TFs)指导,这些转录因子结合特定的基序,招募共激活剂/抑制剂和转录机制。鉴定与 GBM 相关的 TFs-基因调控网络可能揭示新的、可靶向的神经胶质瘤发生机制。
我们在计算机上预测了 GBM 中的 TFs 调节网络,并将其与在人类神经胶质瘤细胞和 GBM 患者样本中可及染色质中鉴定的假定 TF 结合位点进行了交叉。探索了癌症基因组图谱和神经胶质瘤图谱数据集(DNA 甲基化、H3K27 乙酰化、转录组谱),以阐明 TFs-基因调控网络和表观遗传背景的影响。与大多数肿瘤相反,c-Jun 在 GBM 中的表达高于正常大脑,并且在 GBM 中过表达的多个基因中发现了 c-Jun 结合位点,包括 VIM、FOSL2 或 UPP1。凝胶迁移和超迁移实验证明,c-Jun 与 VIM 基因启动子的结合在 GBM 衍生细胞中比在良性神经胶质瘤衍生细胞中更强。与良性神经胶质瘤相比,c-Jun 靶基因的大多数调控区域在 GBM 中具有不同的 DNA 甲基化模式,表明 DNA 甲基化对 c-Jun 依赖性基因表达的贡献。
在 GBM 中鉴定的 GBM 特异性 TFs-基因网络与归因于良性脑肿瘤的调节途径不同,并暗示 c-Jun 在控制驱动神经胶质瘤生长和侵袭的基因方面具有决定性作用,以及 DNA 甲基化的调节作用。